Company Description:
Real Estate Developers and Managers
Real Estate Developers and Managers
Construction Executive Online
Construction Job Openings
Company News
- Can-Fite's Massive $685M Partnership Revenue Forecast: 4 Major Disease Treatments in Pipeline - Stock Titan (news.google.com)
- Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships - Yahoo Finance (news.google.com)
- Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol - GlobeNewswire (news.google.com)
- Can-Fite's Breakthrough: New Pet Arthritis Drug Targets Massive $3.8B Market Opportunity - Stock Titan (news.google.com)
- Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market - GlobeNewswire (news.google.com)
- Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix - Business Wire (news.google.com)
- Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome - Business Wire (news.google.com)
- David Fite Obituary (1932 - 2020) - Sacramento, CA - Times Record - Legacy.com (news.google.com)
- Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma - Business Wire (news.google.com)
- CANF - Can-Fite BioPharma Ltd. Latest Stock News & Market Updates - Stock Titan (news.google.com)
- Can-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings - Business Wire (news.google.com)